openPR Logo
Press release

Mary Ann Malack-Ragona Comments on Recent Alzheimer’s Studies Finding That Disease Spreads Through the Brain

02-05-2012 02:35 PM CET | Associations & Organizations

Press release from: Alzheimer's Association Long Island

/ PR Agency: PRMG
Mary Ann Malack-Ragona, Executive Director/Chief Executive Officer, Alzheimer’s Association Long Island, says recent findings from two independent studies showing how Alzheimer’s disease spreads throughout the brain are an indication that researchers may be one step closer to finding a cure for Alzheimer’s disease.

Two studies — one from Columbia University and another from Harvard University — involved genetically engineered mice that were able to produce abnormal human tau proteins in the enthorhinal cortex, which is located behind the ears and toward the middle of the brain. In Alzheimer’s disease, the cells start dying in the middle of the brain. Researchers found what was expected: that tau was found where the dead cells were, and the dying cells in the mice’s enthorhinal cortex were filled with bundled strands of tau.

The studies further showed that tau was transmitted from cell to cell, leaving dead cells in its wake. Since the other cells in that neural network were unable to produce the human tau protein, the only way they could get the protein was to transmit it to every nerve cell in the network. Although the study involved mice, the researchers said the pattern of cell death was similar to what they see in people with Alzheimer’s disease. They concluded that the best solution to prevent cell-to-cell transmission is to develop an antibody that blocks tau.

Currently, 5.4 million people in this country have Alzheimer’s disease and more than 60,000 of them reside on Long Island. By the middle of this century, it is estimated that approximately 14-16 million people will have a diagnosis of Alzheimer’s disease; 1 out of 8 baby boomers is at risk.

“I am very pleased to see that we are getting close to finding what may cause Alzheimer’s disease,” Ms. Malack-Ragona said. “This means researchers could have the necessary building blocks they need to find a cure for Alzheimer’s. It may take a few years before we can confirm these findings, but this is still a positive first step.”

With a National Alzheimer’s Plan currently in the stages of development, Ms. Malack-Ragona is urging elected officials to provide more funding for research. “In order to accelerate the process, the government needs to invest more financial resources into finding a cure for Alzheimer’s,” she said. “With more than 10,000 baby boomers turning 65 every day, their risk for developing Alzheimer’s greatly increases. We are at a critical juncture of the Alzheimer’s crisis and time is of the essence. Alzheimer’s cannot wait.”

For more information, please contact Mary Ann Malack-Ragona, Executive Director/CEO at (631) 820-8068 or visit www.alz.org/longisland.

The Alzheimer's Association is the world’s leading voluntary health organization in Alzheimer’s care, support and research. Our mission is to eliminate Alzheimer’s disease through the advancement of research; to provide and enhance care and support for all affected; and to reduce the risk of dementia through the promotion of brain health. Our vision is a world without Alzheimer’s. For more information, visit www.alz.org.

Hank Russell, Public Relations Director
The Public Relations and Marketing Group
156 North Ocean Avenue
Patchogue, NY 11772
(631) 207-1057
hrussell@theprmg.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Mary Ann Malack-Ragona Comments on Recent Alzheimer’s Studies Finding That Disease Spreads Through the Brain here

News-ID: 209629 • Views:

More Releases for Alzheimer

Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is
Anti-β-Alzheimer Therapies Market : Consumption, Revenue, Applications With Maj …
Alzheimer disease (AD) is a type of dementia that affects memory, thinking, language and behavior. Increasing age and high number of people suffering from Alzheimer's with age 65 and older are the major risk factors for progression of this disorder. It starts with mild symptoms and ends with severe brain damage in which individuals lose the ability to carry on a conversation and respond to their environment. According to Alzheimer
Anti-β-Alzheimer Therapies That Cut Attacks Hailed As 'huge Deal'
Alzheimer disease (AD) is a type of dementia that affects memory, thinking, language and behavior. Increasing age and high number of people suffering from Alzheimer's with age 65 and older are the major risk factors for progression of this disorder. It starts with mild symptoms and ends with severe brain damage in which individuals lose the ability to carry on a conversation and respond to their environment. According to Alzheimer
Alzheimer Diagnostic Tests Market - Medical Devices Pipeline Assessment, 2017 | …
"The Latest Research Report Alzheimer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" About Alzheimer Diagnostic Tests Market GlobalData's Medical Devices sector report, Alzheimer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017" provides an overview of Alzheimer Diagnostic Tests currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports. Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as